I feel naked without my smart watch. I’m honestly addicted to getting my 10k steps and the little dopamine hit I get when my wrist buzzes, telling me I’ve hit a goal.
In awesome news for the health tech obsessed, smart watches are getting smarter.
Leading global consumer electronics developer, Mobvoi has launched the TicWatch GTH Pro which offers advanced heart health tracking with features developed by ATCOR, a CardieX (ASX: CDX) subsidiary.
ATCOR has developed proprietary and now FDA approved SphygmoCor technology which is now the industry standard for measuring central arterial pressure waveforms.
The TicWatch is the product of a two year project between the two companies. The whole watch was designed around integration of ATCOR’s heart health biometric system allowing users useful insights into their cardiovascular health. Wearers will be able to view insights into their exercise capacity, arterial ‘age’, heart stress and heart rate. All data is measured non invasively from sensors in the watch.
In addition to ATCOR’s tech, Mobvoi’s watches integrate Wear OS, Google’s operating system, offering all the trimmings you expect to find in a smart watch.
Note that the watch itself isn’t FDA approved, but ATCOR’s tech that’s been integrated into it is.
Craig Cooper, CardieX CEO and Managing Director said: “This is the first integration of our market leading SphygmoCor® heart health technology into a wearable device and has been the result of a significant two-year collaboration with Mobvoi. Our “Arty Heart Health” platform incorporates unique arterial biometrics and heart health insights based on the 20-year legacy of our ATCOR subsidiary in partnering with global research organizations, pharmaceutical companies, and leading clinical practices. It’s this same trusted, clinical grade technology that we are now incorporating into a series of new consumer wearables and home health devices.”
For the half year ending 31st December 2021 the microcap company reported a net loss after tax of $5.1 million and revenues of $2.3. million, a five year record high. Staff costs outstrip any other expense, including research and development leaving the Company with $5.4 million in the bank (as at 31 December 2021) for future operating activities, a cash runway of just over 2 quarters.
Investors could anticipate the ramping up of R&D costs seeing as the Company is seeking to make their own way in the consumer wearables market too, a market currently worth USD $57.3 billion which is expected to grow at a compound annual growth rate of 18.32%.
“The TicWatch GTH Pro is the first in a number of new consumer product releases planned for this year as we continue to move forward with the development, FDA clearance process, and launch of a suite of new wearable and home health devices and apps under our new CONNEQT brand.”
The TicWatch GTH Pro is now available via Mobvoi’s website, Amazon and GTHPro.com for US customers.
Samantha Freidin is a business journalist at Emerald Financial whilst also completing a Masters of Marketing and Digital Communications at Monash University.
Latest posts by Samantha Freidin (see all)
- Parkinson’s UK backs Pharmaxis with $5 million to slow the onset of incurable disease with ‘ground breaking’ trial - September 1, 2022
- How this company is developing medtech to support Indigenous community health - August 22, 2022
- A round of ap-paws for PharmAust, changing the ruff prognosis for dogs with lymphoma - August 17, 2022
Leave a Comment
You must be logged in to post a comment.